Dermatology

Heritability plays more of a factor in pediatric-onset autoimmune diseases than in adult diseases.

Study suggests superior efficacy from older PsA drugs.

Secukinumab shows promise in the treatment of patients with psoriatic arthritis.

Improvements in itching scores maintained from week 16 to week 52 in patients who received Otezla.

Chronic inflammatory skin condition associated with decreased quality of life and increased all-cause mortality.

Lengthening time between treatment with anti-TNF agents may improve adherence.

Mild psoriasis, severe psoriasis, and psoriatic arthritis may also bring increased comorbidities.

Caregivers need to help patients with psoriasis understand the importance of lifestyle behavior choices.

The role of vitamin D in diseases such as psoriatic arthritis, systemic lupus erythematosus, and rheumatoid arthritis.

Discovery holds promise for patients with Crohn's disease, diabetes, ulcerative colitis, and more.

Psoriasis treatment may improve more than just skin issues.

A 10-second assessment may be as effective as more complex tests.

Elevated risk found for heart arrhythmia, specifically atrial fibrillation.

Lithium chloride found to slow degradation.

Patients who received secukinumab sustained improvements over one year of treatment.

Drug decreases enthesitis and dactylitis by blocking the production of cytokines that promote inflammation.

Study finds improved screening needed for condition.

Physical aspects and quality of life issues improve with treatment.

Treatment blocks signals that may lead to inflammation.

Psoriasis treatment among drugs seized by authorities.

Experimental treatment blocks signaling protein.

Genetic variants found that are associated with psoriatic arthritis, but not psoriasis.

Patients with celiac disease are known to be deficient in the amino acid L-carnitine, a nutrient essential for muscle energy production.

Treatment with secukinumab led to clearer skin after 12 weeks compared with placebo.